In summary, SETDB1 could activate AKT T308 and S308 phosphorylation sites by promoting methylation of AKT on K64me3 site, thereby accelerating the tumorigenesis and chemotherapy resistance of HCC cells in nude mice. The gene discussed is AKT1; the disease is hepatocellular carcinoma.